🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06808841
Starting soon Not applicable

Sufentanil in Patients With Lower Extremity Fracture Surgery Myocardial Damage Function Study

NCT06808841 · tracked via the Priya Life Science China tracker
Sponsor
Second Hospital of Shanxi Medical University
Phase
Not applicable
Started
2025-02-05
Last updated
2025-02-05

Condition(s) studied

Myocardial Injury

Investigational drug(s) / intervention(s)

Sufentanil injectionPlacebo

Sufentanil injection: Different concentrations of sufentanil were administered to three different subgroups of patients in the same way

Placebo: Placebo

Study summary

1. To analyze the association of different doses of opioids on myocardial injury/protection through BMP-6/SMAD pathway.
2. To observe the effect of different doses of opioids on the expression of BMP-6 in bone marrow.
3. To investigate the relationship between different doses of opioids and BMP-6 and perioperative cardiovascular adverse events in patients with lower extremity fracture surgery.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: * There were 160 patients aged 18-65 years and older who needed surgery for lower extremity fracture. * ASA grades I to III, gender is not limited. Exclusion Criteria: * Patients with acute myocardial infarction in the last 6 months, those with a history of heart failure, and those with elevated troponin levels before injury. * Old fracture * Stroke patients * Liver cirrhosis, kidney failure * Serious systemic infections, alcoholism, drug dependence * Pathological fracture * Use of glucocorticoids in the past one month * Diabetic

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Second Hospital of Shanxi Medical University Taiyuan Shanxi

More Second Hospital of Shanxi Medical University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06808841 on ClinicalTrials.gov ↗ ← All trials in China